Open AccessEffect of apatinib combined with chemotherapy on quality of life and related complications in patients with advanced gastric cancer
Author(s) -
Dunpin Hong,
Yuying Wei,
Aimin Zang,
Zhiyu Wang,
Lin Yang,
Guanying Ren,
Shenyong Su,
Chong Zhang
Publication year - 2022
Publication title -
tropical journal of pharmaceutical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.209
H-Index - 36
eISSN - 1596-5996
pISSN - 1596-9827
DOI - 10.4314/tjpr.v20i8.24
Subject(s) - apatinib , medicine , chemotherapy , gastroenterology , quality of life (healthcare) , cancer , incidence (geometry) , surgery , oncology , physics , nursing , optics
Purpose: To investigate the effect of apatinib combined with chemotherapy on quality of life (QOL) and related complications in patients with advanced gastric cancer (AGC).
Methods: Clinical data for 102 AGC patients treated in The Affiliated Hospital of Hebei University (January 2018 - December 2019) were retrospectively analyzed. The subjects were randomly and equally split into chemotherapy group and combination group. Both groups of patients were treated with 180 mg/m2 of paclitacel, and patients in the combination group were additionally given 500 mg of apatinib daily, for a treatment time to disease remission in both groups. Clinical efficacy, QOL, complications as well as serum SIL-2R, VEGF and TNF-α levels in the two groups were compared to analyze the effect of apatinib combined with chemotherapy on AGC patients.
Results: Disease control rate (DCR) and overall response rate (ORR) of gastric cancer patients in the combination group were notably higher than those in the chemotherapy group (p 0.05). After treatment, the QOL scores of both groups increased significantly, of which QOL score in the combination group was notably higher (p < 0.05).
Conclusion: Apatinib combined with chemotherapy effectively enhances the clinical efficacy of AGC patients, controls the overexpression of serum SIL-2R, VEGF and TNF-α, and improves the QOL of patients without increasing adverse reactions. Therefore, the combination therapy is safe and effective.